VS 002
Alternative Names: VP-002; VS-002Latest Information Update: 29 Feb 2024
At a glance
- Originator University of Florida Research Foundation
- Developer Nuvara Therapeutics
- Class Amino acids; Antidiarrhoeals
- Mechanism of Action Chloride channel modulators; Cystic fibrosis transmembrane conductance regulator modulators; Sodium-hydrogen antiporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diarrhoea
Most Recent Events
- 29 Feb 2024 Nuvara Therapeutics plans a phase II/III clinical trial for Diarrhoea in 2024 (PO) (Nuvara Therapeutics pipeline, February 2024)
- 30 Nov 2021 Nuvara Therapeutics plans for NDA Preparation in 2024 (Nuvara Therapeutics website, November 2021)
- 30 Nov 2021 Nuvara Therapeutics plans for IND submission for phase II/III trial in 2023 (Nuvara Therapeutics website, November 2021)